Concordia Announces Release Date For Second Quarter 2017 Results

OAKVILLE, ON, July 28, 2017 /PRNewswire/ - Concordia International Corp. (“Concordia” or the “Company”) (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to release its second quarter 2017 financial results before market open on Friday, August 11, 2017.

The Company will subsequently hold a conference call that same day, Friday, August 11, 2017, at 8:30 a.m. ET hosted by Mr. Allan Oberman, Chief Executive Officer, and other senior management. A question-and-answer session will follow the corporate update.

This call is being webcast and can be accessed by going to:
http://event.on24.com/r.htm?e=1461798&s=1&k=FE95193B8C06888A3193CD0C7F86F702

An archived replay of the webcast will be available by clicking the link above.

About Concordia
Concordia is a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products. Concordia has an international footprint with sales in more than 90 countries, and has a diversified portfolio of more than 200 established, off-patent products. Concordia also markets Photofrin® for the treatment of certain rare forms of cancer.

The Company operates out of facilities in Oakville, Ontario and, through its subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England and Mumbai, India.

Notice regarding forward-looking statements and information:
This news release includes forwardlooking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forwardlooking information within the meaning of Canadian securities laws, regarding Concordia and its business, which may include, but are not limited to, statements with respect to the release date of Concordia’s financial results. The forwardlooking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Concordia, including risks associated with Concordia’s securities, increased indebtedness and leverage, Concordia’s growth, risks associated with the use of Concordia’s products, the inability to generate cash flows, revenues and/or stable margins, the inability to repay debt and/or satisfy future obligations, risks associated with a delay in releasing Concordia’s financial statements (which could result in a default under Concordia’s debt agreements and a violation of applicable laws), Concordia’s outstanding debt, risks associated with the geographic markets in which Concordia operates and/or distributes its products, risks associated with distribution agreements, the pharmaceutical industry and the regulation thereof, regulatory investigations, the failure to comply with applicable laws, economic factors, market conditions, risks associated with growth and competition, the failure to obtain regulatory approvals, the equity and debt markets generally, general economic and stock market conditions, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), political risks (including changes to political conditions), risks associated with the United Kingdom’s exit from the European Union (including, without limitation, risks associated with regulatory changes in the pharmaceutical industry, changes in crossborder tariff and cost structures and the loss of access to the European Union global trade markets), risks related to patent infringement actions, the loss of intellectual property rights, risks and uncertainties detailed from time to time in Concordia’s filings with the Securities and Exchange Commission and the Canadian Securities Administrators, and many other factors beyond the control of Concordia. Although Concordia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forwardlooking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forwardlooking statement or information can be guaranteed. Except as required by applicable securities laws, forwardlooking statements and information speak only as of the date on which they are made and Concordia undertakes no obligation to publicly update or revise any forwardlooking statement or information, whether as a result of new information, future events, or otherwise.

SOURCE Concordia International Corp.